Extra money in soles
His lab has new data linking sirtuins directly to epigenetic reprogramming, and theyre about to submit a paper for Nature
Laterality Codes: ICD-10 can specify the side of the body affected (right, left, or bilateral), allowing for more precise diagnosis and treatment
[DOI] [PubMed] [Google Scholar] 336.Ding S., Xu S., Ma Y., Liu G., Jang H., Fang J
doi: 10.1016/j.biocel.2014.08.011
Insurance Coverage Predictions CagriSema (Advantage: Semaglutide Component): Leverages Wegovy's established coverage "Combination of proven medication + new molecule" easier sell to insurers Predicted coverage: 50-60% of commercial plans initially Retatrutide (Challenge: Novel Molecule): Entirely new drug class, no established coverage Higher efficacy but also higher side effects Will likely require trial-and-failure of cheaper options Predicted coverage: 40-50% of commercial plans initially Clinical Trial Populations and Indications CagriSema: Diabetes Focus REDEFINE-1: Obesity without diabetes (3,417 participants) REDEFINE-2: Obesity WITH type 2 diabetes (1,206 participants) REIMAGINE Program: Additional diabetes-focused trials Advantage: Strong diabetes data positions CagriSema for dual obesity + diabetes indications, like tirzepatide (Mounjaro/Zepbound)
